Investor Alert

New York Markets Close in:

press release

Feb. 2, 2022, 7:00 a.m. EST

Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

WALTHAM, Mass., (BUSINESS WIRE) -- Deciphera Pharmaceuticals, Inc. /zigman2/quotes/203556943/composite DCPH +0.29% today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the following investor conferences:

  • Guggenheim 2022 Oncology Virtual Conference on February 9, 2022 at 8:30 AM ET

  • 11 [th] Annual SVB Leerink Global Healthcare Conference on February 16, 2022 at 3:40 PM ET

A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at . A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK [®] is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit and follow us on LinkedIn and Twitter (@Deciphera).

View source version on

SOURCE: Deciphera Pharmaceuticals, Inc.

Investor Relations:
Maghan Meyers
Argot Partners
212-600-1902 Media:
David Rosen
Argot Partners


Is there a problem with this press release? Contact the source provider Comtex at You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2022

US : U.S.: Nasdaq
$ 13.96
+0.04 +0.29%
Volume: 49,360
July 7, 2022 9:57a
P/E Ratio
Dividend Yield
Market Cap
$921.73 million
Rev. per Employee


Partner Center

Link to MarketWatch's Slice.